Evidence map›Paper›PMID 36777418›Full record

ArticleCrohn's & colitis 3602022

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients.

Marieke J Pierik, Andrea E van der Meulen, Klaas Van der Linde, Maurice Lutgens, Johan P Kuijvenhoven, Halil Akol, Ids J Klompmaker, Michelle S G Sikkens, Yvonne J B van Megen, Corinne M Stoop and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Crohn's & colitis 360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marieke J PierikDivision of Gastroenterology and Hepatology, MUMC, Maastricht, The Netherlands.
Andrea E van der MeulenDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0000-0001-9353-5431
Klaas Van der LindeDepartment of Gastroenterology and Hepatology, MCL, Leeuwarden, The Netherlands.
Maurice LutgensDepartment of Gastroenterology and Hepatology, Elisabeth Tweesteden Ziekenhuis, Tilburg, The Netherlands.
Johan P KuijvenhovenDepartment of Gastroenterology and Hepatology, Spaarne Gasthuis, Haarlem, The Netherlands.ORCID https://orcid.org/0000-0002-6802-360X
Halil AkolDepartment of Gastroenterology and Hepatology, MC De Veluwe, Apeldoorn, The Netherlands.
Ids J KlompmakerDepartment of Gastroenterology and Hepatology, Wilhelmina Ziekenhuis Assen, Assen, The Netherlands.
Michelle S G SikkensDepartment of Gastroenterology-Hepatology, Dijklander Ziekenhuis, Enkhuizen, The Netherlands.
Yvonne J B van MegenMedical Department, Mundipharma Pharmaceuticals B.V., Leusden, The Netherlands.
Corinne M StoopMedical Department, Mundipharma Pharmaceuticals B.V., Leusden, The Netherlands.
Joanne P J Bloemsaat-MinekusMedical Department, Mundipharma Pharmaceuticals B.V., Leusden, The Netherlands.ORCID https://orcid.org/0000-0001-8545-7568
Gerard DijkstraDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Quality of life (QoL) data for patients with inflammatory bowel disease switched from the reference infliximab to biosimilar CT-P13 is lacking. This study aims to demonstrate noninferiority for QoL and efficacy after switching. Methods: OoL and clinical efficacy were measured prior to and after 2, 4, and 6 CT-P13 infusions. Results: One hundred seventy-eight patients were included. Noninferiority was established for QoL [ratio 97.95% (95% confidence interval 95.93 to 100.01)] and efficacy [difference -0.02 (95% confidence interval -0.68 to 0.64)]. Five patients reported 6 nonrelated, serious adverse events. Conclusions: Switching from reference infliximab to CT-P13 did not affect the QoL or disease activity and was well tolerated.

Indexed as

biosimilarinflammatory bowel diseaseinfliximabquality of life

Identifiers

PMID36777418
PMCPMC9802295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.